Hepatitis B News and Research RSS Feed - Hepatitis B News and Research

Hepatitis B is one type of hepatitis – a liver disease- caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen or other body fluid. An infected woman can give hepatitis B to her baby at birth.

If you get HBV, you may feel as if you have the flu, or you may have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to scarring of the liver, liver failure or liver cancer.

There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine.
New text message alert system helps parents remember child's vaccination appointments

New text message alert system helps parents remember child's vaccination appointments

Nearly a third of all children nationwide and in Kentucky aren't up-to-date with the vaccination schedule recommended by the Centers for Disease Control (CDC), but not because their parents are refusing vaccines. Evidence suggests parents tend to forget appointments when children are scheduled to receive immunizations. [More]
No effect of baseline cirrhosis on long-term TDF treatment outcomes

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment. [More]
Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas. [More]
New resource available to help older Chinese Americans better understand their healthcare needs

New resource available to help older Chinese Americans better understand their healthcare needs

On the eve of National Minority Health Month, which helps raise awareness for disparities in health and care among minorities in the U.S., a new resource is available to help one such group, older Chinese Americans, better understand and drive their own well-being. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
WHO report: Access to new medicines requires transparency, collaboration

WHO report: Access to new medicines requires transparency, collaboration

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe. [More]
Study: HBV exposure increases immune system maturation of infants

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B. [More]
New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center. [More]
New vaccine for post exposure treatment of rabies infection enters human clinical trial

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide. [More]
HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend. [More]
Long-term entecavir, TDF effective in chronic HBV in real-world setting

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis. [More]
Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates. [More]
Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Johns Hopkins Bloomberg School of Public Health researchers say that major disruptions in the health care systems in West Africa caused by the Ebola crisis have led to significant decreases in vaccinations for childhood diseases, increasing susceptibility to measles and other vaccine-preventable illnesses. [More]
Study describes the dual role of microRNA during hepatitis C infection

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery. [More]
WHO releases first-ever guidance for chronic hepatitis B treatment

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year - most of them in low- and middle-income countries. [More]
Understanding strengths and weaknesses of hepatitis C viruses

Understanding strengths and weaknesses of hepatitis C viruses

Using a specially selected library of different hepatitis C viruses, a team of researchers led by Johns Hopkins scientists has identified tiny differences in the pathogens' outer shell proteins that underpin their resistance to antibodies. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. [More]
Women for Positive Action introduces new educational tool for women living with HIV

Women for Positive Action introduces new educational tool for women living with HIV

To mark International Women's Day (March 8, 2015), Women for Positive Action has launched a practical and informative new educational tool entitled 'Hepatitis and coinfection in women living with HIV'. Led by a global, multidisciplinary group of experts, Women for Positive Action is committed to addressing the specific concerns of women living with HIV. [More]
Advertisement
Advertisement